Condition
Hematoma, Subdural
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT05491356Phase 4CompletedPrimary
Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas
NCT06415422Not ApplicableNot Yet RecruitingPrimary
Platelet Activity Monitoring for Patients Under Adp Medication Using Verify Now in Subdural Hematoma
Showing all 2 trials